Alan I. Edrick
Analyst · CRT Capital
Thank you, Deepak. Our continued focus on driving higher-margin growth initiatives and operating improvements throughout the company has succeeded in delivering significant earnings. As we start our fiscal '14, we are excited about the prospects for both revenue and earnings growth. I'll speak more to our guidance shortly. But first, let me review in more detail the financial results for the fourth quarter. Net revenues in the quarter were down 3% versus Q4 last year. Revenues from our Security division decreased 18% in the fourth quarter, primarily due to the impact of the U.S. Army integration contract I mentioned earlier. Excluding the prior year impact on revenues from this program, Security division had robust sales growth. Our Opto division continued its strong top line momentum, with 24% sales growth for the quarter as a result of continuing success in broadening our customer base. And finally, though our Healthcare division revenues dipped by 2% in Q4 year-over-year, it was up 41% sequentially, as we mentioned earlier. The fourth quarter gross margin of 38.2% was very encouraging, up by a significant 380 basis points from the same quarter last year. This increase was mainly driven by our better mix of revenue in our Security division, including increased turnkey security sales. The margin expansion is particularly noteworthy since our lowest gross margin division, Opto, experienced significant sales growth, which places pressure on the overall company gross margin. Moving to OpEx. Q4 SG&A saw only a modest increase over the prior year despite the ramp up in Mexico and additional bad debt expense. All divisions have done an admirable job increasing efficiencies and managing the cost structure. We continue to invest significant resources in R&D to enhance our Security and Healthcare product offerings. Our R&D spending as a percentage of revenues was 5.6% in the fourth quarter of fiscal '13, which was just slightly lower than the comparable quarter in '12. We focus our efforts on innovative products and technologies to add value to our Security and Healthcare product offerings and to enhance future growth. We are seeing the results of these efforts in a number of new products that are being released. Restructuring and other charges were $3 million in the quarter, primarily related to the move to our new Healthcare headquarters which, as Deepak mentioned, not only will facilitate growth but is expected to result in substantial cost savings over many years. Please note this move was completed in 2 phases, the first of which occurred in our fourth quarter and the second of which will be completed in our first quarter of fiscal '14. We are currently anticipating restructuring and other charges of approximately $3 million in connection with the second phase of the move and the consolidation of one of our Opto facilities. These charges are excluded from our non-GAAP EPS. Our effective tax rate for fiscal '13 was 26.6%, excluding the impact of a noncash tax charge of $6.8 million. This charge was incurred as a result of electing to accelerate the depreciation for tax purposes of certain fixed assets related to our Mexico turnkey program. Mexican tax law afforded us the opportunity to save approximately $26 million of taxes in fiscal '13 by accelerating the depreciation of fixed assets. By making this election, portions of the tax basis of the underlying assets were forfeited, resulting in a noncash tax charge in the year the election is made. In addition to saving cash taxes in the near term, this election to accelerate depreciation was made fairly obvious because the tax lives of the underlying assets exceed the 6-year initial term of the program by up to 14 years, thus potentially resulting in the forfeiture of a large portion of the cost of the fixed assets. Including this noncash tax charge, our effective tax rate was 36.4%. Our provision for income taxes is dependent on the mix of income from U.S. and foreign locations, due to tax rate differences among countries, as well as the impact of permanent taxable differences and valuation allowances, among other items. Gross margin expansion, coupled with solid cost management, led to Q4 earnings per share of $1.02 as compared to $0.79 in the comparable prior year period, excluding restructuring and other charges, as well as the noncash tax charge noted previously, which represents a 29% increase. The GAAP EPS, including these restructuring and other charges and a noncash tax charge, was $0.58. Moving to cash flow. As we mentioned on recent quarterly calls, we expected to see significant volatility in cash flow in fiscal '13, primarily as a result of the Mexico turnkey program. Our cash flow from operations in fiscal '13 was $59 million. This operating cash flow was used to partially fund our capital expenditures, which totaled $157 million for the year. This is consistent with our previous guidance that CapEx would be significantly higher than historical norms in support of our Mexico turnkey program. Our year end DSO increased over the prior year as a significant portion of 2012 Q4 sales were collected in the same quarter prior to year end, whereas a larger portion of our Q4 '13 sales have already been or expected to be collected in Q1 of '14. Partially offsetting the rise in DSO was a corresponding increase in days payables. In addition, we repurchased approximately 12 million in stock during fiscal '13. We expect the current business to lead to solid cash flow in the future as we generate significant cash, with most of the initial CapEx spending on Mexico behind us soon. Finally, turning to our fiscal 2014 guidance. With the solid outlook for each of our businesses, our revenue guidance for fiscal '14 is $870 million to $895 million, which represents 8% to 12% year-over-year growth. As you know from past calls, we provide overall company guidance. Rather than by division or program. We anticipate diluted earnings per share of $3.22 to $3.38, excluding impairment, restructuring and other charges, which represents 17% to 22% growth on a non-GAAP basis over fiscal '13. This range factors in increased investments in R&D and a higher effective tax rate. We are working on and investing in a number of new innovative R&D programs, which we will share at the appropriate time in the future. With this, we expect such costs to rise somewhat in proportion to our sales growth in fiscal '14. During the past few years, we have transformed our company and as a result, we have consistently delivered a strong bottom line along with significant operating cash flow. The investments we have made have enabled us to be the leader in turnkey screening solutions and strengthened our other businesses, allowing the company to perform well despite a challenging worldwide economic environment. We believe we are well positioned for continuous strong growth in the coming years, and we look forward to sharing our progress on upcoming calls. Thank you for listening to this conference call. And at this time, we'd like to open the call to questions.